Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

KRAS mutation-independent downregulation of MAPK/PI3K signaling in colorectal cancer.

Molecular oncology - 1 Mar 2022

Lam Kuen Kuen, Tang Choong Leong, Tan Emile, Wong Siew Heng, Cheah Peh Yean

Abstract excerpt

KRAS is a gatekeeper gene in human colorectal tumorigenesis. KRAS is 'undruggable'; hence, efforts have been diverted to inhibit downstream RAF/MEK/ERK and PI3K/Akt signaling. Nevertheless, none of these inhibitors has progressed to clinical use despite extensive trials. We examined levels of phospho-ERK1/2(T202/Y204) and phospho-Akt1/2/3(S473) in human colorectal tumor compared to matched mucosa with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Line, Tumor
Share to Colorectal Neoplasms
Share to Down-Regulation

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Mitogen-Activated Protein Kinase Kinases

Share to Phosphatidylinositol 3-Kinases

Share to Proteomics

Share to Proto-Oncogene Proteins c-akt

Share to Proto-Oncogene Proteins p21(ras)

Source

Open in PubMed Open full text

Identifiers

PMID: 34919787
DOI: 10.1002/1878-0261.13163
PMCID: PMC8895447

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

KRAS mutation-independent downregulation of MAPK/PI3K signaling in colorectal cancer.PMID 34919787Read ↗

Similar but different: distinct roles for KRAS and BRAF oncogenes in colorectal cancer development and therapy resistance.Semantic proximity Read ↗

An overview of KRAS-targeting therapies for colorectal cancer in phase I and II development.Semantic proximity Read ↗

KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer.Semantic proximity Read ↗

Genome-wide CRISPR-cas9 knockout screening identifies GRB7 as a driver for MEK inhibitor resistance in KRAS mutant colon cancerSemantic proximity Read ↗

Differential gene expression signatures between colorectal cancers with and without KRAS mutations: Crosstalk between the KRAS pathway and other signalling pathwaysSemantic proximity Read ↗

Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers.Semantic proximity Read ↗

ERK-dependent protein phosphorylation in KRAS-mutant cancer: a mix of the expected and surprising.Semantic proximity Read ↗

Oncogenic Kras drives invasion and maintains metastases in colorectal cancer.Semantic proximity Read ↗

Inhibition of PI3K/Akt/mTOR signaling in PI3KR2-overexpressing colon cancer stem cells reduces tumor growth due to apoptosisSemantic proximity Read ↗

Cell type-dependent differential activation of ERK by oncogenic KRAS in colon cancer and intestinal epitheliumSemantic proximity Read ↗

SHANK3 depletion leads to ERK signalling overdose and cell death in KRAS-mutant cancers.Semantic proximity Read ↗

Cell type-dependent differential activation of ERK by oncogenic KRAS in colon cancer and intestinal epitheliumSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.